Join Growin Stock Community!

Shuttle pharmaceuticals holdings, inc.SHPH.US Overview

US StockHealthcare
(No presentation for SHPH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SHPH AI Insights

SHPH Overall Performance

SHPH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SHPH Recent Performance

-3.00%

Shuttle pharmaceuticals holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SHPH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SHPH Key Information

SHPH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SHPH Profile

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

Price of SHPH

SHPH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SHPH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.52
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-10.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.52
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%

  • When is SHPH's latest earnings report released?

    The most recent financial report for Shuttle pharmaceuticals holdings, inc. (SHPH) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SHPH's short-term business performance and financial health. For the latest updates on SHPH's earnings releases, visit this page regularly.

  • How much debt does SHPH have?

    As of the end of the reporting period, Shuttle pharmaceuticals holdings, inc. (SHPH) had total debt of 667.33K, with a debt ratio of 0.19. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SHPH have?

    At the end of the period, Shuttle pharmaceuticals holdings, inc. (SHPH) held Total Cash and Cash Equivalents of 2.09M, accounting for 0.59 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SHPH's EPS continuing to grow?

    According to the past four quarterly reports, Shuttle pharmaceuticals holdings, inc. (SHPH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SHPH?

    Shuttle pharmaceuticals holdings, inc. (SHPH)'s Free Cash Flow (FCF) for the period is -2.63M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 31.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SHPH?

    The latest valuation data shows Shuttle pharmaceuticals holdings, inc. (SHPH) has a Price-To-Earnings (PE) ratio of -0.35 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.